RS20050563A - Acylaminothiazole derivatives, preparation method thereof and use of same as beta-amyloid peptide production inhibitors - Google Patents

Acylaminothiazole derivatives, preparation method thereof and use of same as beta-amyloid peptide production inhibitors

Info

Publication number
RS20050563A
RS20050563A YUP-2005/0563A YUP20050563A RS20050563A RS 20050563 A RS20050563 A RS 20050563A YU P20050563 A YUP20050563 A YU P20050563A RS 20050563 A RS20050563 A RS 20050563A
Authority
RS
Serbia
Prior art keywords
beta
preparation
same
peptide production
amyloid peptide
Prior art date
Application number
YUP-2005/0563A
Other languages
English (en)
Inventor
Pierre Despeyroux
Daniel Frehel
Bruno Schoentjes
Viviane Van Dorsselaer
Original Assignee
Sanofi-Synthelabo,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo, filed Critical Sanofi-Synthelabo,
Publication of RS20050563A publication Critical patent/RS20050563A/sr
Publication of RS51168B publication Critical patent/RS51168B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ovaj pronalazak odnosi se na jedinjenja opšte formule (I). Rečena jedinjenja mogu se upotrebljavati kao inhibitori proizvodnje β-amiloid peptida tako što inhibiraju gama proteaze.
YUP-2005/0563A 2003-01-23 2004-01-22 Derivati acilaminotiazola, njihovo dobijanje i njihova upotreba kao inhibitora proizvodnje beta-amiloid peptida RS51168B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300703A FR2850380B1 (fr) 2003-01-23 2003-01-23 Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
PCT/FR2004/000140 WO2004067520A1 (fr) 2003-01-23 2004-01-22 Derives d'acylaminothiazole, leur preparation et leur utilisation en tant qu’inhibiteurs de la production du peptide beta-amyloide

Publications (2)

Publication Number Publication Date
RS20050563A true RS20050563A (en) 2007-06-04
RS51168B RS51168B (sr) 2010-10-31

Family

ID=32669150

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0563A RS51168B (sr) 2003-01-23 2004-01-22 Derivati acilaminotiazola, njihovo dobijanje i njihova upotreba kao inhibitora proizvodnje beta-amiloid peptida

Country Status (24)

Country Link
US (2) US7563903B2 (sr)
EP (1) EP1590337B1 (sr)
JP (1) JP2006515888A (sr)
KR (1) KR101059669B1 (sr)
CN (1) CN100532370C (sr)
AR (1) AR042745A1 (sr)
AT (1) ATE404545T1 (sr)
AU (1) AU2004207658B2 (sr)
BR (1) BRPI0406893A (sr)
CA (1) CA2511610A1 (sr)
DE (1) DE602004015726D1 (sr)
FR (1) FR2850380B1 (sr)
HR (1) HRP20050637A2 (sr)
IL (1) IL169428A (sr)
MA (1) MA27610A1 (sr)
ME (1) MEP16708A (sr)
MX (1) MXPA05007847A (sr)
NO (1) NO330415B1 (sr)
NZ (1) NZ541147A (sr)
PL (1) PL377999A1 (sr)
RS (1) RS51168B (sr)
RU (1) RU2360907C2 (sr)
TW (1) TWI320710B (sr)
WO (1) WO2004067520A1 (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009344A2 (en) * 2003-06-05 2005-02-03 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
AU2007207743B2 (en) * 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
WO2009108760A2 (en) 2008-02-26 2009-09-03 Board Of Regents, The University Of Texas System Dendritic macroporous hydrogels prepared by crystal templating
EP2371421A1 (en) * 2010-03-04 2011-10-05 Université de Lille 2 Droit et Santé Ligands of insulin degrading enzyme and their uses
EP2508511A1 (en) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN103145692B (zh) * 2013-03-12 2014-07-16 盐城工学院 一种4,5-二氢-6H-环戊烷并[b]噻吩-6-酮的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069075A (ko) * 1996-11-22 2000-11-25 진 엠. 듀발 Ｎ-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법
ES2319239T3 (es) * 1996-12-23 2009-05-05 Elan Pharmaceuticals, Inc. Cicloalquilo, lactama, lactona y compuestos relacionados, composiciones farmaceuticas que comprenden los mismos y procedimientos para inhibir la liberacion del peptido beta-amiloide y/o sintesis mediante el uso de tales compuestos.
ES2237919T4 (es) * 1998-06-18 2007-05-01 Bristol-Myers Squibb Company Inhibidores aminotiazol sustituidos con carbono de quinasas dependientes de ciclina.
AU6229699A (en) * 1998-10-26 2000-05-15 Sumitomo Pharmaceuticals Company, Limited Beta-amyloid formation inhibitors
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios

Also Published As

Publication number Publication date
CA2511610A1 (en) 2004-08-12
NO330415B1 (no) 2011-04-11
IL169428A (en) 2010-12-30
BRPI0406893A (pt) 2006-01-03
MA27610A1 (fr) 2005-11-01
FR2850380A1 (fr) 2004-07-30
MEP16708A (en) 2010-06-10
EP1590337A1 (fr) 2005-11-02
PL377999A1 (pl) 2006-02-20
TWI320710B (en) 2010-02-21
EP1590337B1 (fr) 2008-08-13
MXPA05007847A (es) 2006-05-17
WO2004067520A1 (fr) 2004-08-12
DE602004015726D1 (de) 2008-09-25
AU2004207658B2 (en) 2009-10-29
JP2006515888A (ja) 2006-06-08
NZ541147A (en) 2008-06-30
RU2360907C2 (ru) 2009-07-10
KR101059669B1 (ko) 2011-08-25
AU2004207658A1 (en) 2004-08-12
FR2850380B1 (fr) 2006-07-07
HRP20050637A2 (en) 2005-10-31
TW200503699A (en) 2005-02-01
KR20050094039A (ko) 2005-09-26
US7879889B2 (en) 2011-02-01
CN100532370C (zh) 2009-08-26
AR042745A1 (es) 2005-06-29
US20060052426A1 (en) 2006-03-09
RS51168B (sr) 2010-10-31
US7563903B2 (en) 2009-07-21
NO20053588D0 (no) 2005-07-22
NO20053588L (no) 2005-09-22
ATE404545T1 (de) 2008-08-15
RU2005126608A (ru) 2006-04-27
CN1777593A (zh) 2006-05-24
US20090253753A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
YU5503A (sh) Nesteroidni supresori zapaljenja
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
IL173810A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MXPA06010097A (es) Inhibidores de dipeptidil peptidasa-iv.
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
MXPA06000921A (es) Derivados de benzamidazoles como inhibidores de mek.
PL1758852T3 (pl) Podstawione związki cyklopentenu
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
TW200626564A (en) Carboxylic acid derivative containing thiazole ring and medical use thereof
EP1831239B8 (en) A process for the preparation of 17-hydroxy-6 beta, 7 beta, 15 beta, 16 beta -bismethylene-17 alpha-pregn-4-ene-3-one-21-carboxylic acid gamma-lactone and key-intermediates for this process
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
WO2004031145A3 (en) Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
WO2005005389A3 (en) Malonamide derivatives
MXPA05010875A (es) Derivados de piperazina como inhibidores de renina.
RS20060297A (en) Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics
TNSN05277A1 (en) Novel bioisosteres of actinonin
IL173895A0 (en) Imidazopyridine derivatives and pharmaceutical compositions containing the same
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
TW200719889A (en) Amino acid derivatives
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
TW200624429A (en) Novel cysteine protease inhibitors
RS20050563A (en) Acylaminothiazole derivatives, preparation method thereof and use of same as beta-amyloid peptide production inhibitors
HK1091816A1 (en) Diphenylurea derivatives and their use as chloride channel blockers
WO2005058841A3 (en) Hiv protease inhibiting compounds